Zacks Investment Research

Selected news for the capital firm - Zacks Investment Research, collected since 10/2017. Recent stories appear in dispatchtribunal.com and theenterpriseleader.com. This capital firm shares healthcare news with Oncology, Medical Research, Biotech, Biopharma, Infectious Disease and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/9/2021 Q1 2022 Earnings Estimate for Tivity Health, Inc. Issued By Piper Sandler (NASDAQ:TVTY) rivertonroll.com ... March 4th. Barrington Research boosted their target price on shares of Tivity Health from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday, February 25th. Finally, Zacks Investment Research downgraded shares of Tivity Health from a “buy” rating to a “hold” rating in a research note on Thursday, March 25th. One analyst has rated the stock with a sell rating ...
5/9/2021 ClearPoint Neuro (NASDAQ:CLPT) Stock Rating Lowered by Zacks Investment Research - WKRB News wkrb13.com ... well as for performing biopsies.See Also: What does an inverted yield curve signify?Get a free copy of the Zacks research report on ClearPoint Neuro (CLPT)For more information about research offerings from Zacks Investment Research, visit Zacks.com ...
5/9/2021 Zacks Investment Research Downgrades AdaptHealth (NASDAQ:AHCO) to Hold slatersentinel.com Zacks Investment Research Downgrades AdaptHealth (NASDAQ:AHCO) to Hold Posted by Trina Covell on May 9th, 2021AdaptHealth (NASDAQ:AHCO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports.According to Zacks, “AdaptHealth Corp. is a provider of home medical equipment primarily in the United States. It offers medical products for both rental and ...
5/9/2021 Q2 2021 Earnings Estimate for Inspire Medical Systems, Inc. (NYSE:INSP) Issued By Piper Sandler Mayfield Recorder ... EPS, Q3 2022 earnings at ($0.37) EPS, Q4 2022 earnings at ($0.19) EPS and FY2022 earnings at ($1.66) EPS. Get Inspire Medical Systems alerts:Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Inspire Medical Systems from a “hold” rating to a “sell” rating in a report on Wednesday, April 28th. Robert W. Baird restated a “buy” rating on shares ...
5/8/2021 Analysts Anticipate Tivity Health, Inc. (NASDAQ:TVTY) Will Post Quarterly Sales of $110.13 Million Dakota Financial News Brokerages forecast that Tivity Health, Inc. (NASDAQ:TVTY) will report sales of $110.13 million for the current quarter, according to Zacks Investment Research . Five analysts have made estimates for Tivity Health’s earnings, with the highest sales estimate coming in at $114.69 million and the lowest estimate coming in at $105.71 million. Tivity Health reported sales of $262.60 million during the same quarter last year, which indicates a negative year ...
5/8/2021 $110.13 Million in Sales Expected for Tivity Health, Inc. (NASDAQ:TVTY) This Quarter dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsAnalysts forecast that Tivity Health, Inc. (NASDAQ:TVTY) will announce sales of $110.13 million for the current fiscal quarter, according to Zacks Investment Research . Five analysts have made estimates for Tivity Health’s earnings, with the highest sales estimate coming in at $114.69 million and the lowest estimate coming in at $105.71 million. Tivity Health posted sales of ...
5/8/2021 Zacks: Analysts Anticipate Tivity Health, Inc. (NASDAQ:TVTY) to Announce $0.35 EPS theenterpriseleader.com Zacks: Analysts Anticipate Tivity Health, Inc. (NASDAQ:TVTY) to Announce $0.35 EPS Posted by Maurice Goldstein on May 8th, 2021Brokerages expect that Tivity Health, Inc. (NASDAQ:TVTY) will report earnings per share (EPS) of $0.35 for the current quarter, according to Zacks Investment Research . Five analysts have made estimates for Tivity Health’s earnings, with estimates ranging from $0.31 to $0.38. Tivity Health posted earnings per share of $0.79 ...
5/8/2021 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Post Quarterly Sales of $94.05 Million - Ticker Report Ticker Report Wall Street brokerages expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to announce $94.05 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $93.50 million to $94.60 million. Ironwood Pharmaceuticals reported sales of $89.43 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.2%. The business is ...
5/8/2021 Zacks Investment Research Downgrades Outset Medical (NASDAQ:OM) to Hold baseballnewssource.com Zacks Investment Research Downgrades Outset Medical (NASDAQ:OM) to Hold Posted by Andrew Walz on May 8th, 2021 TweetOutset Medical (NASDAQ:OM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Zacks.com reports.According to Zacks, “Outset Medical Inc. is a medical technology company. Its Tablo(R) Hemodialysis System represents technological advancement enabling ...
5/8/2021 Zacks: Brokerages Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Announce $0.10 Earnings Per Share Dakota Financial News Brokerages expect Coherus BioSciences, Inc. (NASDAQ:CHRS) to announce earnings of $0.10 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Coherus BioSciences’ earnings. The highest EPS estimate is $0.11 and the lowest is $0.09. Coherus BioSciences reported earnings per share of $0.70 in the same quarter last year, which would suggest a negative year over year growth rate of 85.7%. The ...
5/8/2021 ProPhase Labs (NASDAQ:PRPH) Downgraded by Zacks Investment Research to “Hold” dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsProPhase Labs (NASDAQ:PRPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.According to Zacks, “ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered ...
5/8/2021 SVB Leerink Equities Analysts Raise Earnings Estimates for Silk Road Medical, Inc (NASDAQ:SILK) dispatchtribunal.com ... FY2022 earnings at ($1.23) EPS, FY2023 earnings at ($0.54) EPS and FY2024 earnings at ($0.19) EPS. Get Silk Road Medical alerts:A number of other research analysts have also recently issued reports on SILK. Zacks Investment Research raised shares of Silk Road Medical from a “sell” rating to a “hold” rating in a research note on Wednesday. Citigroup lowered their target price on shares of Silk Road Medical ...
5/8/2021 HORIBA (OTCMKTS:HRIBF) Downgraded to “Hold” at Zacks Investment Research dispatchtribunal.com ... provides vehicle development engineering and testing engineering services; and leases and manages R&D facilities.Get a free copy of the Zacks research report on HORIBA (HRIBF)For more information about research offerings from Zacks Investment Research, visit Zacks.com HORIBA HORIBA ...
5/8/2021 William Blair Weighs in on Lucira Health, Inc.'s Q1 2021 Earnings (NASDAQ:LHDX) dispatchtribunal.com ... 0.34) EPS, Q3 2022 earnings at ($0.35) EPS, Q4 2022 earnings at ($0.30) EPS and FY2022 earnings at ($1.30) EPS. Get Lucira Health alerts:Several other brokerages have also recently issued reports on LHDX. Zacks Investment Research cut Lucira Health from a “hold” rating to a “sell” rating in a research report on Wednesday. Bank of America reaffirmed an “underperform” rating and set a $9.00 target price ...
5/8/2021 OraSure Technologies (NASDAQ:OSUR) Stock Price Up 6.7% After Better-Than-Expected Earnings - Watch List News watchlistnews.com ... March 2nd. Lake Street Capital dropped their price objective on shares of OraSure Technologies from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Friday. One investment analyst ...
5/8/2021 Zacks: Analysts Anticipate STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Will Announce Quarterly Sales of $6.73 Million | Daily Political Daily Political ... with estimates ranging from $30.20 million to $33.64 million. For the next fiscal year, analysts forecast that the business will report sales of $35.89 million, with estimates ranging from $35.70 million to $36.09 million. Zacks Investment Research ’s sales calculations are an average based on a survey of sell-side analysts that follow STRATA Skin Sciences.STRATA Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings results on Tuesday, March 23rd ...
5/8/2021 Equities Research Analysts’ Updated EPS Estimates for May, 8th (NBRV, NDLS, NGM, NJR, NSIT, NVMI, NVST, NWN, OCBI, OCFT) - American Banking News American Banking News Equities Research Analysts’ Updated EPS Estimates for May, 8th (NBRV, NDLS, NGM, NJR, NSIT, NVMI, NVST, NWN, OCBI, OCFT)Equities Research Analysts’ updated eps estimates for Saturday, May 8th:Nabriva Therapeutics (NASDAQ:NBRV) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to ...
5/8/2021 Zacks Investment Research Upgrades Tabula Rasa HealthCare (NASDAQ:TRHC) to Hold The Markets Daily ... improve medication outcomes, and patient relationships by enhancing their existing programs or systems.Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)For more information about research offerings from Zacks Investment Research , visit Zacks.com Receive News & Ratings for Tabula Rasa HealthCare analysts' ratings for Tabula Rasa HealthCare and related companies daily email newsletter ...
5/8/2021 Tabula Rasa HealthCare (NASDAQ:TRHC) Upgraded to Hold at Zacks Investment Research Dakota Financial News ... by enhancing their existing programs or systems.Featured Article: Cost of Capital ExplainedGet a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)For more information about research offerings from Zacks Investment Research, visit Zacks.com ...
5/8/2021 NantHealth (NASDAQ:NH) Raised to “Hold” at Zacks Investment Research Mayfield Recorder NantHealth (NASDAQ:NH) Raised to “Hold” at Zacks Investment Research Posted by Cindy Kellogue on May 8th, 2021Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a sell rating to a hold rating in a report published on Friday, Zacks.com reports.According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an ...